Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.

FDA Approves Launches of Vyvanse Generic

On August 25, 2023, several generic drug manufacturers received U.S. Food and Drug Administration (FDA) approval for A-rated generics to Vyvanse® (lisdexamfetamine – Takeda Pharmaceuticals). Lisdexamfetamine is taken once each morning to treat attention deficit hyperactivity disorder (ADHD) for patients at least six years old and binge eating disorder (BED) for adults. A boxed warning cautions that lisdexamfetamine is a Class II controlled (CII) central nervous system (CNS) stimulant with increased potential for abuse and/or dependence. Brand Vyvanse® typically costs about $370 per month while generic lisdexamfetamine is expected to cost approximately $160 per month.

FDA Approves Launches of Vyvanse Generic hero image

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image